$DYAI News

Dyadic Announces Japan Patent Office Allowance Of Claims Covering Its Proprietary Thermothelomyces Heterothallica Recombinant Protein Expression Technology

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

Dyadic Highlights Increasing Interest In Proprietary C1 Protein Production Platform As Global Infectious Disease Preparedness Efforts Intensify In Response To Ongoing Bundibugyo Ebola Virus Outbreak

Dyadic (DYAI) Q1 2026 Earnings Call Transcript

Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

Dyadic's Applied Biosolutions Unit Collaborates With Scripps Research To Evaluate Monoclonal Antibody And Vaccine Candidates Targeting Hantaviruses, Including Andes Virus

Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

DYAI: First Quarter Results

Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference

Dyadic International, Inc. Q1 2026 Earnings Call Summary

Dyadic International Inc (DYAI) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...

Dyadic International, Inc. (DYAI) Q1 2026 Earnings Call Transcript

Transcript: Dyadic International Q1 2026 Earnings Conference Call

Dyadic International Inc (NASDAQ:DYAI) Q1 Report Beats Revenue Expectations but EPS Miss Triggers 28% After-Market Selloff

Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress

Transcript: Dyadic International Q1 2026 Earnings Conference Call

Dyadic International Q1 EPS $(0.05) Misses $(0.04) Estimate, Sales $1.111M Beat $900.000K Estimate

Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026

DYAI: Introducing AlbuFree DX

Dyadic International Gets Nasdaq Warning Over Listing Rules, Faces Delisting Risk